Featured
| Nov 06 | Stem cells can tailor their role in gene therapy based on the underlying disease, study suggests read more » |
| Nov 04 | HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration read more » |
| Nov 01 | Navigating the RNA Lipid Nanoparticle Landscape read more » |
| Nov 06 | Hospital-Based CGT Production the Best Option for Patients read more » |
| Nov 06 | Research team discovers a new mechanism in cancer cell immune evasion read more » |
| Nov 05 | Notch Therapeutics Signals a New Era in CAR-T Therapies read more » |
| Nov 04 | What will it take to get miRNA therapies to market? | Nature Biotechnology read more » |
| Nov 01 | Direct RNA Sequencing Supports Novel Discoveries in RNA Biology read more » |
| Nov 01 | The Golden Age of Medicine: Advancements in Novel Modalities and Therapeutic Areas read more » |
| Nov 05 | Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer read more » |
| Nov 05 | Expression and distribution of rAAV9 intrathecally administered in juvenile to adolescent mice read more » |
| Nov 03 | Decoding the epigenetics and chromatin loop dynamics of androgen receptor-mediated transcription read more » |
| Nov 01 | Development of compact transcriptional effectors using high-throughput measurements in diverse contexts read more » |
| Oct 25 | Adeno-Associated Virus Gene Transfer Ameliorates Progression of Skeletal Lesions in Mucopolysaccharidosis IVA Mice read more » |
| Oct 24 | Lentiviral Vector-Mediated Ex Vivo Hematopoietic Stem Cell Gene Therapy for Mucopolysaccharidosis IVA Murine Model read more » |
| Oct 04 | AAVolve: Concatenated long-read deep sequencing enables whole capsid tracking during shuffled AAV library selection read more » |
PackGene’s Newsletter
Receive the latest news and insights to your inbox.
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services
AAV Packaging Services
READ MORE
Off-the-Shelf AAV Products
READ MORE
